Business
Lynparza reduced recurrence risk in breast cancer
Lynparza reduced recurrence risk in breast cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8046A\n AstraZeneca PLC\n 04 June 2021\n \n \n \n \n 3 June 2021 22:00 BST\n \n \n \n \n \n \n Lynparza\n \n \n reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial\n \n \n \n \n \n \n First medicine targeting BRCA mutations to show clinical benefit in adjuvant setting\n \n \n \n \n \n Results from the OlympiA Phase III trial showed AstraZeneca and MSD's Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in invasive disease-free survival (iDFS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.\n \n \n \n \n \n The results will be presented during the plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on 6 June 2021 (abstract LBA#1) and were published today in The New England Journal of Medicine.\n \n \n \n An estimated 2.3 million people were diagnosed with breast cancer worldwide in 2020 and BRCA mutations are found in approximately 5% of breast cancer patients.1,2\n \n \n \n Sue Friedman, Executive Director, Facing Our Risk of Cancer Empowered (FORCE) and member of the OlympiA trial steering committee, said: \"While there have been great strides in the early treatment of breast cancer, the fear of cancer returning is still at the forefront of patients' minds. New targeted treatment approaches are needed in the adjuvant setting that can help keep cancer and that fear at bay.\"\n \n \n \n \n \n Andrew Tutt, chair of the OlympiA trial steering committee and professor of Oncology at The Institute of Cancer Research, London and Kings College London, said: \"We are thrilled that our global academic and industry partnership in OlympiA has been able to help identify a possible new treatment option for patients with early-stage breast cancer and who have inherited mutations in their BRCA1 or BRCA2 genes. Patients with early-stage breast cancer who have inherited BRCA mutations are typically diagnosed at a younger age compared to those without such a mutation. Olaparib has the potential to be used as a follow-on to all the standard initial breas...